MetaCap

NeOnc Technologies (NTHI) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeOnc Technologies (NTHI) has outperformed Upstream Bio (UPB) over the past year, losing 46.2% versus a loss of 93.8%. NeOnc Technologies is the larger company by market cap ($90.9 million vs $87.2 million), about 1.0 times the size, while Upstream Bio is growing revenue faster (+20.4% vs -51.8%). Upstream Bio converts more of its revenue into profit, with a net margin of -5026.0% versus -155404.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NTHI-46.25%UPB-93.78%
+92%-5%-103%
Nov 21, 20251 yearNov 20, 2026
NTHI-80.97%UPB-76.86%
+374%+134%-105%
Mar 24, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NTHI versus UPB key metrics
MetricNTHIUPB
Share price$3.15$1.59
Market cap$90.88M$87.15M
1-day change-9.48%-20.50%
YTD return-61.91%-94.14%
1-year return-46.25%-93.78%
EPS (TTM)$-1.95$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$39.99K$2.85M
Revenue growth (YoY)-51.82%+20.42%
Net income (latest FY)$-62.15M$-143.44M
Operating margin-145637.52%-5618.82%
Net margin-155404.38%-5026.03%
52-week high$11.38$33.68
52-week low$2.50$1.56
Distance from 52-week high-72.31%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside+439.68%+1245.91%
Average volume187.23K1.01M
Shares outstanding28.85M54.81M
Employees575
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NTHI has outperformed UPB by 47.5 percentage points over the past year.
  • Upstream Bio is more profitable, keeping -5026.0 cents of every revenue dollar as net income versus -155404.4 cents for NeOnc Technologies.
  • Upstream Bio grew revenue faster in its latest fiscal year (+20.42% vs -51.82%).

About NeOnc Technologies

NTHI stock →

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

NTHI vs UPB FAQ

Which is bigger, NeOnc Technologies or Upstream Bio?

NeOnc Technologies (NTHI) is larger, with a market capitalization of $90.88M compared with $87.15M for Upstream Bio (UPB).

Which stock has performed better over the past year, NTHI or UPB?

NTHI returned -46.25% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are NeOnc Technologies and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons